Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination and related disorders are often difficult to treat and frequently resistant to change, often rendering conventional modes of treatment (e.g., psychotherapy and pharmacology) unsuccessful. A recent renaissance of psychedelic research shows promise in treating psychopathology with potential for acting on ruminative processes. Though theoretical explanations for the therapeutic effects of psychedelics implicate the reduction of rumination via changes in the default mode network, a limited number of studies have tested this link directly. This mini-review examined the existing empirical research linking psychedelic use and rumination. The results from six studies demonstrate a significant association between psychedelic use and lower levels of rumination, providing evidence that rumination may serve as a key cognitive factor in psychedelic treatment. Further research should explore whether identifying ruminative tendencies and encouraging the practice of disengaging from rumination before the psychedelic treatment session, particularly for those who report high levels of rumination, may result in better adherence to "letting go" during the session. Moreover, due to a possible diminishing effect of therapeutic outcomes after a single psychedelic dosing session, "booster" sessions may provide psychological relief once more; however, financial treatment costs are expectedly high. As such, understanding the role of rumination in psychedelic treatment can be critical for maintenance strategies (e.g., rumination-focused cognitive behavior therapy, mindfulness techniques) in postdosing integration sessions and long-term treatment plans.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658672 | PMC |
http://dx.doi.org/10.1089/psymed.2024.0009 | DOI Listing |
Sci Rep
March 2025
Department of Physiology and Pharmacology, Western University, London, Canada.
Cannabis use in pregnancy is associated with low birthweight outcomes. Recent preclinical data suggests that maternal Δ9-tetrahydrocannabinol (THC) exposure leads to decreases in birthweight followed by early cardiac deficits in offspring. Currently, no studies have explored an intervention for these maternal THC-induced deficits.
View Article and Find Full Text PDFBiol Psychiatry
March 2025
Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression due to the reduced risk of mania induction, research on RAADs, such as (es)ketamine, remains scarce despite their demonstrated safety and effectiveness.
View Article and Find Full Text PDFJ Child Adolesc Psychopharmacol
March 2025
Mayo Clinic Children's Research Center, Mayo Clinic, Rochester, MN, USA.
Cancer Med
March 2025
Medical Oncology, Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
Purpose: To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychological distress.
Content: Pain is a common symptom of cancer and treatment. However, there are high rates of undertreatment of cancer pain due to the complex underlying biology of the condition, and potentially due to a decrease in opioid prescribing in response to the opioid epidemic.
Psychedelic Med (New Rochelle)
March 2024
Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana, USA.
Introduction: Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal dosing. Intravenous (IV) dosing is rapid onset and quickly titrated, possibly preceded by an anxiolytic for patient comfort. We explored the viability of IV psilocin with and without preadministration of lorazepam for possible future inpatient therapeutic utility.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!